An HPLC area percentage can be useful, but it does not answer every qualification question. A buyer still needs to know whether the main peak is the intended material, whether the method can separate relevant components, and whether the allocated lot meets the specification agreed for the order.
Review the number together with the method, chromatogram and traceability record. This guide follows the intended-purpose approach in ICH Q2(R2). It does not set a universal purity threshold or replace a laboratory's quality system.
What an HPLC result does and does not mean
Reverse-phase HPLC separates sample components under stated chromatographic conditions and records detector response over time. A reported area percentage usually compares the integrated area of a selected peak with the integrated areas included by the data-processing method. Its meaning therefore depends on separation, detection and integration choices.
The result is not automatically the net peptide content of the vial. It also does not, by itself, prove molecular identity, water content, residual solvents, counterion content, sterility, endotoxin status or fitness for a particular experiment. Each of those questions needs an appropriate specification and, where required, a separate test.
Start with the buyer's requirement
Before comparing CoAs, write down the material identity, form, intended laboratory use, required quantity and acceptance criteria. A label such as "research grade" or "pharmaceutical grade" is too broad to substitute for this list.
| Question | What to record | Why it matters |
|---|---|---|
| What material is required? | Name, sequence or chemical identity, salt or counterion, modification and physical form | Near-name products and different forms may not be equivalent. |
| What must the method show? | Assay, related components, identity support or another stated purpose | Validation is tied to the procedure's intended purpose. |
| What is acceptable? | Result limits, reporting threshold and treatment of unspecified peaks | A percentage has no pass/fail meaning without a specification. |
| Which lot is being bought? | Allocated lot or a written pre-allocation boundary | A sample CoA from another lot is not batch evidence for the order. |
CoA and chromatogram review checklist
- Match identity and traceability. The product name, lot number and form should agree across the quotation, label, CoA and supporting files.
- Find the specification beside the result. A result without its acceptance criterion cannot show whether the lot passed the agreed requirement.
- Identify the method. Look for a method reference or version and enough context to understand column chemistry, mobile-phase program, detector and sample preparation.
- Review the full relevant run. Confirm that the chromatogram includes the analysis window needed to assess the reported result rather than only a cropped main peak.
- Check integration rules. The report should make clear which peaks were included, excluded or manually reintegrated. Unexplained exclusions deserve a written answer.
- Check system suitability. Review the criteria defined for the method and whether the run met them. Do not import generic limits from another procedure.
- Confirm review and date. The record should identify when the analysis was approved and by whom or by which controlled quality function.
Read the chromatogram without overclaiming
Start with the axes, injection identifier and method reference. Then inspect the baseline, peak separation and integration marks. A large main peak may coexist with a relevant co-eluting component. A visually small peak may also deserve attention if the specification treats it separately.
Ask for clarification when the trace is cropped, the baseline changes abruptly, peaks appear outside the integration window, or the reported area total cannot be reconciled with the displayed integrations. These are questions for the data owner, not proof of a failed lot on their own.
Use ICH Q2(R2) as a validation framework
ICH Q2(R2) connects analytical procedure performance to intended purpose. Depending on that purpose, a validation package may address specificity or selectivity, range, accuracy, precision and robustness. Detection or quantitation limits may matter for procedures that measure low-level components. The guideline does not turn one chromatographic setup into a universal peptide method.
For a method transfer or independent confirmation, obtain the controlled procedure and pre-agree the comparison rules. Column identity, instrument configuration, preparation, processing parameters and reference materials can all affect reproducibility.
A defensible lot-qualification workflow
- Send the material requirement and acceptance criteria with the quote request.
- Ask which batch documents are available for the product and allocated lot.
- Compare the quotation, CoA, chromatogram and label fields before approval.
- Resolve unexplained method, traceability or integration differences in writing.
- Use independent or incoming testing where the buyer's risk assessment requires it.
- Record the accepted lot, document versions, reviewer and decision date.
Dr. Peptides confirms product specifications, available batch documents, pricing and destination-specific delivery options with each quote. Document scope can vary by product, allocated lot and availability. Products are supplied for laboratory research use only and are not intended for human or animal consumption.
Primary reference
- ICH Q2(R2): Validation of Analytical Procedures, International Council for Harmonisation.
Frequently Asked Questions
Can an HPLC purity result prove peptide identity?
No. An HPLC result describes detector response under a defined separation method. Identity needs suitable orthogonal evidence, such as mass-spectrometric or other identity data, when required by the specification.
Why can two HPLC methods report different area percentages for the same sample?
Columns, gradients, detectors, sample preparation and integration rules can change which components separate and how their signals are counted. Compare results only after reviewing the method and its suitability for the intended purpose.
What should I request with a peptide CoA?
Request the product and lot identifiers, agreed specification, result and method reference, the relevant chromatogram, system-suitability evidence, approval date and any additional batch documents required by your risk assessment.
Does ICH Q2(R2) prescribe one HPLC method for every peptide?
No. ICH Q2(R2) provides a framework for validating analytical procedures according to their intended purpose. The relevant performance characteristics and acceptance criteria must be defined for the actual procedure.
Does every Dr. Peptides quote include the same analytical package?
No universal package is promised. Available batch documents depend on the product, allocated lot and quoted specification, and should be confirmed before the order is approved.